AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference
Rhea-AI Summary
AEON Biopharma (NYSE: AEON), a clinical-stage biopharmaceutical company developing a botulinum toxin complex through a 351(k) biosimilar pathway, has announced its participation in the upcoming Leerink Global Healthcare Conference. The event will take place from March 10-12, 2025 in Miami, FL.
Marc Forth, the company's President and Chief Executive Officer, will deliver a corporate overview during the conference. Interested parties can arrange one-on-one meetings with management through their Leerink representatives.
Positive
- None.
Negative
- None.
News Market Reaction – AEON
On the day this news was published, AEON declined 21.31%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
IRVINE, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, today announced that Marc Forth, AEON’s President and Chief Executive Officer, will present a corporate overview at the Leerink Global Healthcare Conference being held March 10 – 12, 2025 in Miami, FL.
Leerink Global Healthcare Conference
| Format: | Corporate Presentation | |
| Date/time: | Monday, March 10 at 1:00-1:30 PM ET | |
| Location: | Miami, FL | |
If you are interested in setting up a one-on-one meeting with management during the conference, please contact your Leerink representative.
About AEON Biopharma
AEON is a clinical stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical conditions, with an initial focus on the neurosciences market. ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus under the name Jeuveau. ABP-450 is manufactured by Daewoong in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by the U.S. Food and Drug Administration, Health Canada and European Medicines Agency. The product is approved as a biosimilar in Mexico and India. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. The Company has built a highly experienced management team with specific experience in biopharmaceutical and botulinum toxin development and commercialization. To learn more about AEON, visit www.aeonbiopharma.com.
Contacts
Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
Source: AEON Biopharma
FAQ
When is AEON Biopharma presenting at the Leerink Global Healthcare Conference 2025?
What is AEON Biopharma's main product development focus?
Who will represent AEON Biopharma at the Leerink Healthcare Conference?
How can investors meet with AEON Biopharma's management at the Leerink conference?
